IMC Chicago’s Acadia Pharmaceuticals ACAD Stock Holding History

IMC Chicago’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$887K	Buy	+44,000	New	+$1.18M	﹤0.01%	4029

Other funds holding ACAD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

IMC Chicago's ACAD Position: Q3 2026 in Review

IMC Chicago sold out of Acadia Pharmaceuticals (ACAD) in Q3 2026, closing a stake of 8,959 shares — an estimated $240K sold.

IMC Chicago first reported a position in ACAD in Q2 2026 and held it in 1 quarter. The position peaked at $227K in Q2 2026. 137 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

IMC Chicago reported no remaining Acadia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
IMC Chicago sold 8,959 Acadia Pharmaceuticals shares in Q3 2026, an estimated $240K.
IMC Chicago first reported a position in Acadia Pharmaceuticals in Q2 2026 and held it in 1 quarter.
IMC Chicago's Acadia Pharmaceuticals position peaked at $227K in Q2 2026.
137 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.